comparative effectiveness

Research in Review

Combination Therapy Improves Outcomes for Patients With CLL

03/10/2017

JCP Editors

The addition of a novel monoclonal antibody to ibrutinib significantly improves survival outcomes for patients with previously treated high-risk chronic lymphocytic leukemia (CLL), according to the results of a phase...

The...

03/10/2017

Journal of Clinical Pathways

Research in Review

Cetuximab Therapy for Anal Carcinoma Associated With Improved Outcomes, High Toxicity

03/03/2017

JCP Editors

Adding cetuximab to chemoradiation for squamous cell carcinoma of the anal canal is associated with lower incidence of locoregional failure but high toxicity, according to the results of a study published in the...

Adding...

03/03/2017

Journal of Clinical Pathways

Department

Genomics of Estrogen Receptor-Positive Cancer Changes Following Metastasis

02/13/2017

JCP Editors

A genomic analysis revealed significant differences in the genomic landscape of estrogen receptor (ER)-positive metastatic breast cancers when compared with ER-positive primary tumors. These alterations frequently...

A...

02/13/2017

Journal of Clinical Pathways

Research in Review

Combination Treatment Improves Survival for BRAF-Mutant Metastatic Colorectal Cancer

01/26/2017

JCP Editors

The addition of BRAF-inhibitor vemurafenib to irinotecan and cetuximab chemotherapy treatment improves progression-free survival (PFS) for patients with BRAF-mutant metastatic colorectal cancer, according to a...

The...

01/26/2017

Journal of Clinical Pathways

Research in Review

Immune Checkpoint Inhibitor New Standard of Care for MSI-H Metastatic Colorectal Cancer

01/25/2017

JCP Editors

The immune checkpoint inhibitor nivolumab has shown durable responses and disease control in pretreated patients with DNA mismatch repair deficient/microsatellite instability high (MSI-H) metastatic colorectal...

The...

01/25/2017

Journal of Clinical Pathways

Research in Review

PET Scans During Induction Chemo Contribute to Complete Response for Esophageal Cancer

01/19/2017

JCP Editors

Positron emission tomography (PET) scans during induction chemotherapy for esophageal cancer helps assess patient response to treatment and adjust their therapy, which could lead to an improved complete response rate...

...

01/19/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Without Chemotherapy May Treat Type of Lymphoma

01/06/2017

JCP Editors

Patients with mantle cell lymphoma may be able to forego chemotherapy in favor of induction treatment with a two-drug regimen, according to new research presented at the American Society of Hematology (ASH) annual...

...

01/06/2017

Journal of Clinical Pathways

Research in Review

Three-Drug Regimen Does Not Improve Prostate Cancer Survival

01/05/2017

JCP Editors

Progression-free survival (PFS) is not improved in patients with metastatic castration-resistant prostate cancer (mCRPC) when enzalutamide is added to abiraterone acetate with prednisone, compared with abiraterone...

...

01/05/2017

Journal of Clinical Pathways

Research in Review

Two-Drug Regimen Plus Bortezomib Improves Survival for Patients With Multiple Myeloma

12/29/2016

JCP Editors

The addition of bortezomib to lenalidomide with dexamethasone treatment significantly improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma, according to new clinical...

The...

12/29/2016

Journal of Clinical Pathways

Research in Review

Proton Pump Inhibitors May Decrease Survival for Patients With Gastric Cancer

12/19/2016

JCP Editors

Over-the-counter heartburn and gastrointestinal drugs, such as proton pump inhibitors (PPIs), may decrease the effectiveness of chemotherapy in patients with gastroesophageal cancer (GEC), according to a new study...

...

12/19/2016

Journal of Clinical Pathways